<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE mutation PUBLIC "mutation" "hrgm.dtd">
<mutation>
  <publication>
    <authorlist>Fu Y, Rope R, Fargue S, Cohen HT, Holmes RP, Cohen DM</authorlist>
    <title>A mutation creating an out-of-frame alternative translation initiation site in the GRHPR 5'UTR causing primary hyperoxaluria type II</title>
    <journal>Clin Genet</journal>
    <year>2014</year>
    <volume>[Epub ahead of print]</volume>
    <pages>doi: 10.1111/cge.12541</pages>
    <pmid>25410531</pmid>
  </publication>
  <variantlist>
    <variant genotype="heterozygous" class="5UTR">
      <build>37</build>
      <chromosome>9</chromosome>
      <pos>37422743</pos>
      <ref>TGC</ref>
      <alt>TAT</alt>
      <snippet>GCACT[GC/AT]GGATG</snippet>
      <regulator>GRHPR 5'UTR</regulator>
      <pathomechanism>5UTR|uORF|reduced-translation|novel-uORF</pathomechanism>
      <validation>
        <reporter direction="down">0.00</reporter>
      </validation>
    </variant>
    <variant genotype="heterozygous" class="coding">
      <build>37</build>
      <chromosome>9</chromosome>
      <pos>37430601</pos>
      <ref>TC</ref>
      <alt>T</alt>
      <snippet>TCTT[C/-]CAGAAGA</snippet>
      <regulator>coding</regulator>
      <pathomechanism>coding</pathomechanism>
      <validation>
        <cosegregation present="yes"/>
        <comparability present="yes"/>
        <other direction="demonstrated">Coding</other>
      </validation>
    </variant>
  </variantlist>
  <disease>
    <name>Hyperoxaluria, primary, type II</name>
    <database>OMIM</database>
    <id>260000</id>
  </disease>
  <phenotypelist>
    <phenotype>
      <hpoid>HP:0008672</hpoid>
      <hponame>Calcium oxalate nephrolithiasis</hponame>
    </phenotype>
    <phenotype>
      <hpoid>HP:0012622</hpoid>
      <hponame>Chronic kidney disease</hponame>
    </phenotype>
  </phenotypelist>
  <identifier></identifier>
  <metadata>Primary hyperoxaluria type II is a recessive genetic disorder caused by mutations in the GRHPR gene. Here, a compound heterozygos patient is reported. The first mutation was a frameshift mutation, c.694delC, i.e., NM_012203.1:c.694delC, p.(Gln232Argfs*3), corresponding to chr9:37,430,603delC (GRCh37; the GRHPR gene is located on the plus strand of chromosome 9). The other variant is located in the 5' UTR of GRHPR, NM_012203.1:c.-4_-3delGCinsAT. This allele is predicted to direct pre-mature out-of-frame translational initiation and synthesis of a 20-amino acid peptide (MDETGATHEGVRHPQDTRRG) bearing no relation to GRHPR. An SV40-driven luciferase reporter downstream of the variant 41-bp GRHPR 5 ′ UTR exhibited marked hypoactivity relative to the wild-type 5'UTR. This confirmed that, in the presence of the upstream out-of-frame translational start site, negligible translation occurred from the more distal native initiation site, and probably giving rise to a profoundly hypomorphic allele in vivo. Therefore, the novel dinucleotide 5 ′ UTR variant, through introduction of a high-efficiency out-of-frame alternative translational start site, was a strongly hypomorphic allele. The two mutated nucleotides are located at chr9:37,422,744-37,422,745 (GRCh37).</metadata>
  <targetgene>
    <entrezid>9380</entrezid>
    <genesymbol>GRHPR</genesymbol>
  </targetgene>
  <biocurator>HPO:probinson</biocurator>
  <datecreated>1452066549479</datecreated>
  <datemodified>1452066549480</datemodified>
</mutation>
